Leukemia: Comprehensive Clinical Overview
Epidemiology
Leukemia accounts for approximately 2.5% of all new cancer incidence globally and 3.1% of cancer-related mortality, with an age-standardized incidence rate of 5.4 per 100,000 and mortality rate of 3.3 per 100,000 1. The disease burden varies significantly by subtype and geography:
- Acute Lymphoblastic Leukemia (ALL): Primarily affects children
- Acute Myeloid Leukemia (AML): Most common acute leukemia in adults, accounting for the largest number of annual leukemia deaths in the United States 2
- Chronic Lymphocytic Leukemia (CLL): Most common adult leukemia in Western countries, with median age at diagnosis of 72 years 3
- Chronic Myelogenous Leukemia (CML): More common in adults
Geographic patterns show higher incidence in highly developed regions and among White populations in the United States 4. Recent trends show overall decreasing incidence and mortality in most countries, though increases have been observed in Germany, Korea, Japan, Canada, and the UK for incidence, and in the Philippines, Ecuador, Belarus, and Thailand for mortality 1.
Risk Factors
Established Risk Factors 5, 4:
- Age: Increasing risk with advancing age
- Ionizing radiation exposure: Well-documented causal relationship
- Chemical exposures:
- Benzene and hydrocarbons (particularly from auto repair garages and petrol stations for pediatric cases)
- Formaldehyde
- Butadiene
- Genetic disorders: Down syndrome significantly increases risk
- Immunosuppression: Including HIV/AIDS-related immunodeficiency
Lifestyle and Metabolic Factors (Country-Level Associations) 1:
- Smoking prevalence
- Physical inactivity
- Overweight and obesity
- Hypercholesterolemia
Socioeconomic Indicators:
- Human Development Index
- GDP per capita (associated with higher incidence, likely reflecting better detection)
Critical caveat: Ethnicity matters prognostically—Hispanics have the worst outcomes in ALL, higher incidence of Philadelphia chromosome-positive/BCR-ABL1-like ALL, and increased risk of treatment-related adverse effects including pancreatitis 6.
Pathophysiology
Leukemia results from abnormal proliferation of hematopoietic stem cells in the bone marrow, leading to accumulation of malignant cells that displace normal hematopoiesis 7. The pathophysiology varies by subtype:
- Acute leukemias: Rapid accumulation of immature blast cells
- Chronic leukemias: Slower accumulation of more mature but still abnormal cells
- Molecular basis: Involves chromosomal translocations, gene mutations, and epigenetic alterations that disrupt normal cell differentiation and proliferation control
Clinical Presentation
Common Symptoms Across All Subtypes 7:
- Constitutional symptoms: Fever, fatigue, weight loss
- Bone marrow failure manifestations:
- Easy bruising or bleeding (thrombocytopenia)
- Recurrent infections (neutropenia)
- Pallor and dyspnea (anemia)
- Musculoskeletal: Joint pain, bone pain
- Organomegaly: Hepatomegaly, splenomegaly
- Lymphadenopathy
- Cutaneous lesions (in some cases)
- Neurologic findings (particularly with CNS involvement)
Physical Examination Findings 6:
- Organomegaly assessment
- Lymph node examination
- Skin examination for leukemic infiltrates
- Neurologic examination
Critical Initial Assessment 6:
- Document ethnicity/race (prognostic significance)
- Environmental/occupational exposure history (benzene, hydrocarbons, formaldehyde, ionizing radiation)
- Family history of hematologic disorders or genetic syndromes
Diagnostic Criteria and Initial Workup
Essential Clinical Data Collection 6:
For CLL specifically: Diagnosis requires ≥5 × 10⁹/L clonal B lymphocytes with characteristic phenotype (CD19+, CD5+, CD20+, CD23+, with kappa or lambda restriction) maintained for ≥3 months 3. Cytopenia from bone marrow infiltrate establishes diagnosis regardless of lymphocyte count.
Laboratory Studies
Mandatory Initial Tests 6:
- Complete blood count with differential
- Comprehensive metabolic panel
- Lactate dehydrogenase (tumor burden marker, tumor lysis syndrome risk)
- Uric acid and phosphate (tumor lysis syndrome assessment)
- Coagulation panel: PT, PTT, fibrinogen (essential for acute promyelocytic leukemia/DIC detection)
- Blood type and screen
Specimen Collection 6, 8:
The pathologist or treating clinician should obtain peripheral blood and bone marrow aspirate with core biopsy for comprehensive evaluation 6.
Key principle: If peripheral blood shows sufficient blasts, perform complete ancillary studies on blood specimen—additional bone marrow flow cytometry becomes unnecessary if blood flow cytometry is diagnostic 6.
Investigations
Morphologic Evaluation 6:
For suspected acute leukemia, the pathologist should evaluate Wright-Giemsa-stained peripheral blood smear and bone marrow aspirate smears 6. Core biopsy provides architectural assessment and cellularity.
Immunophenotyping 6:
Flow cytometry immunophenotyping is mandatory for diagnosis and classification 6. The analysis must be comprehensive enough to allow subsequent minimal residual disease (MRD) detection 6.
Critical caveat: If bone marrow aspirate is insufficient, immunohistochemistry on core biopsy can provide limited immunophenotyping, or obtain second core biopsy in tissue culture medium for disaggregation 6.
Cytogenetic and Molecular Testing
For Pediatric B-ALL 6:
The pathologist or treating clinician should ensure testing for:
- t(12;21)(p13.2;q22.1); ETV6-RUNX1
- t(9;22)(q34.1;q11.2); BCR-ABL1
- KMT2A (MLL) translocations
- iAMP21
- Trisomy 4 and 10
For Adult B-ALL 6:
Testing for t(9;22)(q34.1;q11.2); BCR-ABL1 is mandatory 6. KMT2A (MLL) translocation testing may be performed.
Additional ALL Testing 6:
- B-ALL: PAX5, JAK1, JAK2, IKZF1 mutations; CRLF2 overexpression
- T-ALL: NOTCH1, FBXW7 mutations
- BCR-ABL1-like ALL markers: ABL-class fusions, JAK-STAT pathway alterations (actionable with tyrosine kinase inhibitors) 6
For AML (All Ages) 6:
FLT3-ITD testing is mandatory 6. Additional recommended mutations include:
- IDH1, IDH2
- TET2
- WT1
- DNMT3A
- TP53 (independent poor prognostic factor)
For acute promyelocytic leukemia: FISH or PCR for PML-RARA should be performed immediately 6.
For core-binding factor AML (with t(8;21) or inv(16)/t(16;16)): KIT mutation testing is mandatory in adults (strong recommendation), expert consensus in pediatrics 6.
For other AML cases: NPM1, CEBPA, and RUNX1 mutation analysis should be performed 6.
For CLL 9, 3:
Mandatory testing:
- FISH with 4-probe panel (del(17p), del(11q), trisomy 12, del(13q))
- IGHV mutational status before first treatment
- TP53 mutation detection before first treatment and at each relapse
Cerebrospinal Fluid Evaluation 6:
For ALL patients receiving intrathecal therapy, CSF sampling is mandatory 6. Perform cell count and cytocentrifuge preparation with blast enumeration reviewed by pathologist.
For other acute leukemias, CSF may be obtained when clinically indicated without contraindications 6.
Extramedullary Disease 6:
When extramedullary disease presents without bone marrow involvement, tissue biopsy must be processed for morphology, immunophenotyping, cytogenetics, and molecular genetics as recommended for bone marrow 6.
Specimen Preservation 6:
Cryopreserved cells, nucleic acid, formalin-fixed paraffin-embedded tissue, or unstained smears may be used for validated molecular/genetic studies, with proper identification and storage in compliant laboratories 6.
Management
Acute Myeloid Leukemia
Older Adults (ASH 2025 Guidelines) 10:
Treatment should be pursued over best supportive care alone in appropriate candidates 10. The decision framework prioritizes:
For patients with favorable prognosis: Consider traditional induction therapy
For non-favorable prognosis:
- Venetoclax-based regimens are preferred over monotherapies 10
- Hypomethylating agents (HMA) + venetoclax combinations
Targeted therapy integration:
- FLT3 inhibitors should be incorporated into induction and post-remission therapy for FLT3-mutated AML 10
- IDH inhibitors for IDH-mutated disease
Post-remission therapy: Role and duration should be individualized based on risk stratification
Hematopoietic stem cell transplantation: Consider in non-favorable prognosis AML with suitable candidates
Transfusion support: Maintain for patients no longer receiving antileukemic therapy
Chronic Lymphocytic Leukemia
Treatment Initiation Criteria 9, 3:
Treatment should begin in symptomatic patients with iwCLL criteria for active disease. Targeted therapies are prioritized over immunochemotherapy 9.
First-Line Treatment 9, 3:
For del(17p) and/or TP53 mutation:
- Second-generation covalent BTK inhibitor (ibrutinib or acalabrutinib) administered indefinitely is the optimal choice 9
For patients without del(17p)/TP53 mutation:
Mutated IGHV:
- Time-limited venetoclax + obinutuzumab is first-line 9
- Alternative: Chemoimmunotherapy (FCR or BR) in fit, younger patients
Unmutated IGHV:
Relapsed/Refractory CLL 9:
- Early relapse: Change therapy to venetoclax + rituximab, ibrutinib, acalabrutinib, or alternative BTK inhibitor 9
- Late relapse without del(17p)/TP53: Ibrutinib, venetoclax + rituximab, or repeat front-line therapy 9
Special Situations 9:
Autoimmune cytopenia: Treat with corticosteroids; if unresponsive, consider anti-CD20 antibodies or BCR inhibitors 9.
Richter's transformation (2-15% of CLL patients) 9:
- Confirm with lymph node biopsy (PET-CT guides biopsy site)
- Determine clonal relationship between DLBCL and CLL via IGHV sequencing
- Clonally-related: Poor prognosis; consider clinical trials; allogeneic stem cell transplant for eligible patients with available donor 9
- Clonally-unrelated: Treat as de novo DLBCL (R-CHOP first-line) 9
Acute Lymphoblastic Leukemia
Treatment varies by age, risk stratification, and molecular features. Philadelphia chromosome-positive ALL requires tyrosine kinase inhibitor integration. BCR-ABL1-like ALL with ABL-class fusions may benefit from TKI therapy 6.
Minimal Residual Disease Monitoring
Flow cytometry analysis or molecular characterization must be comprehensive enough to allow subsequent MRD detection 6. However, except after allogeneic stem cell transplant, MRD measurement is not yet recommended as routine clinical practice 9.
For NPM1-mutated AML, molecular MRD monitoring shows prognostic value, though optimal screening panel size remains unclear 6.
Treatment Complications and Monitoring
Acute Complications 7:
- Tumor lysis syndrome: Monitor electrolytes, uric acid, phosphate, LDH
- Serious infections: From treatment-related immunosuppression
- Cardiovascular events
- Hepatotoxicity
- Disseminated intravascular coagulation: Particularly in acute promyelocytic leukemia
Long-Term Sequelae in Survivors 7:
- Secondary malignancies (solid tumors, MDS, secondary AML)
- Cardiovascular disease
- Musculoskeletal disorders
- Endocrine dysfunction
CLL patients have 2-7 fold increased risk of secondary malignancies 9.
Follow-Up
Life-long observation is recommended for all leukemia patients 9. For asymptomatic patients:
- Blood count every 3-12 months (frequency based on disease dynamics)
- Physical examination: lymph nodes, liver, spleen palpation
- Monitor for autoimmune cytopenia
- Surveillance for secondary malignancies
Prognosis
Five-year survival rates are highest in younger patients and those with chronic myelogenous or chronic lymphocytic leukemia 7. Acute leukemias in adults have poorer survival, while Hodgkin lymphoma has favorable outcomes 4. Survival has improved substantially with targeted therapies, particularly in CLL and Philadelphia chromosome-positive ALL.